

## Special Issue

# Combining Immunotherapy and Targeted Therapies in Cancer Treatment

### Message from the Guest Editors

Cancer is an increasing epidemiological issue worldwide. Molecularly targeted therapies directed at various molecular targets, along with immunotherapy, have fundamentally transformed the therapeutic outlook for patients undergoing radical or palliative treatment for cancer. Targeted therapies are widely utilized in the fields of hematology and oncology. Novel approaches to combination therapy in the context of overcoming resistance represent a compelling subject that merits investigation. This Special Issue warmly welcomes fundamental and translational research, original articles, and concise communications that focus on innovative anti-cancer strategies. Special attention will be given to manuscripts that describe molecular mechanisms of drug resistance, predictive biomarkers, as well as original contributions that present real-world evidence and introduce novel action protocols.

---

### Guest Editors

Dr. Aleksandra Grela-Wojewoda

Prof. Dr. Wojciech Wysocki

Dr. Marek Ziobro

---

### Deadline for manuscript submissions

closed (25 June 2024)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/174956](https://mdpi.com/si/174956)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)